- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Growth Potential Companies
U.S. Pharmaceuticals & Biotech High Growth Potential Companies
Results
160
Companies with a Future performance score of at least 3, ordered by Future performance score.
160 companies
Ascendis Pharma
Market Cap: US$11.5b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
ASND
US$191.99
7D
-2.9%
1Y
32.8%
Travere Therapeutics
Market Cap: US$2.2b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$25.30
7D
1.8%
1Y
80.6%
Alnylam Pharmaceuticals
Market Cap: US$58.9b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$446.40
7D
-1.6%
1Y
62.4%
AVITA Medical
Market Cap: US$162.5m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$5.20
7D
-4.9%
1Y
-51.6%
Axsome Therapeutics
Market Cap: US$5.8b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$116.76
7D
0.7%
1Y
30.3%
TG Therapeutics
Market Cap: US$5.1b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$35.50
7D
9.7%
1Y
49.0%
Zevra Therapeutics
Market Cap: US$534.4m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$9.77
7D
27.4%
1Y
41.2%
Caris Life Sciences
Market Cap: US$8.4b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$29.19
7D
-10.4%
1Y
n/a
Mereo BioPharma Group
Market Cap: US$281.6m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
MREO
US$1.94
7D
11.5%
1Y
-53.1%
Evolus
Market Cap: US$386.8m
A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
EOLS
US$5.99
7D
-4.8%
1Y
-62.4%
Legend Biotech
Market Cap: US$6.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$33.37
7D
-1.9%
1Y
-32.3%
Alvotech
Market Cap: US$2.5b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$8.34
7D
5.8%
1Y
-29.9%
Madrigal Pharmaceuticals
Market Cap: US$9.4b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$424.23
7D
-3.6%
1Y
99.7%
Achieve Life Sciences
Market Cap: US$151.8m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$3.01
7D
6.7%
1Y
-36.9%
Evoke Pharma
Market Cap: US$10.5m
Operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
EVOK
US$4.90
7D
-6.1%
1Y
1.9%
OS Therapies
Market Cap: US$66.8m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$2.05
7D
-3.3%
1Y
-28.8%
Tenaya Therapeutics
Market Cap: US$242.8m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$1.66
7D
17.7%
1Y
-16.4%
Abeona Therapeutics
Market Cap: US$274.9m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.44
7D
1.1%
1Y
-7.6%
ARS Pharmaceuticals
Market Cap: US$942.8m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$9.80
7D
0.1%
1Y
-31.6%
Aldeyra Therapeutics
Market Cap: US$297.2m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.07
7D
2.8%
1Y
-7.8%
Cingulate
Market Cap: US$21.2m
A biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
CING
US$3.81
7D
7.6%
1Y
-24.3%
LENZ Therapeutics
Market Cap: US$1.1b
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$42.03
7D
-0.6%
1Y
74.8%
Soleno Therapeutics
Market Cap: US$3.3b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$64.96
7D
18.7%
1Y
32.2%
Vanda Pharmaceuticals
Market Cap: US$285.4m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$5.10
7D
13.6%
1Y
9.2%
RenovoRx
Market Cap: US$42.9m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.18
7D
-11.3%
1Y
11.3%
Capricor Therapeutics
Market Cap: US$298.1m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$7.09
7D
6.6%
1Y
-28.7%
UroGen Pharma
Market Cap: US$798.5m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$18.34
7D
2.2%
1Y
42.2%
ACADIA Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$21.05
7D
-13.8%
1Y
34.2%
ADMA Biologics
Market Cap: US$3.7b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.61
7D
-1.9%
1Y
-19.5%
Corcept Therapeutics
Market Cap: US$8.7b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$83.87
7D
4.2%
1Y
90.9%
Humacyte
Market Cap: US$255.7m
Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
HUMA
US$1.73
7D
-7.0%
1Y
-69.0%
Eton Pharmaceuticals
Market Cap: US$540.1m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$21.27
7D
16.0%
1Y
266.7%
Grace Therapeutics
Market Cap: US$42.6m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$3.09
7D
-0.3%
1Y
-1.0%
Arcutis Biotherapeutics
Market Cap: US$2.0b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$17.57
7D
1.1%
1Y
87.7%
Citius Oncology
Market Cap: US$152.0m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$2.00
7D
13.6%
1Y
42.9%
Syndax Pharmaceuticals
Market Cap: US$1.3b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$15.68
7D
6.1%
1Y
-17.0%